Vertex Pharmaceuticals stock has delivered a strong 155.4% return over the past 5 years, yet the current valuation picture is mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to some upside while the broader checks look less supportive.

• Over 5 years, Vertex Pharmaceuticals has returned 155.4%, which puts recent pricing against a backdrop of already strong gains.
• Expectations around new therapies and pipeline catalysts may support the current share price, while competitive pressure in cystic fibrosis treatments can weigh on how much investors are willing to pay for future cash flows.
• On Simply Wall St's broader checklist, Vertex Pharmaceuticals scores 2 out of 6 on valuation, which suggests the stock does not screen as a clear bargain even though the intrinsic value estimate sits about 12.5% above the recent price.

The issue now is whether Vertex Pharmaceuticals' share price already reflects most of that intrinsic value upside or still leaves a reasonable margin based on current expectations.

Is Vertex Pharmaceuticals a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) method values Vertex Pharmaceuticals based on the cash the business is expected to generate for shareholders. Vertex produced about $3.79b in free cash flow over the latest twelve months, and the model assumes these cash flows keep growing rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity model points to an intrinsic value of about $567 per share.

With the current share price sitting roughly 12.5% below this estimate, Vertex Pharmaceuticals appears undervalued on this cash flow view. Vertex’s raised 2026 revenue guidance and the planned acquisition of Crinetics help explain why analysts use a growing cash flow base in the model, even as competition in cystic fibrosis adds some uncertainty.

On balance, the DCF output indicates that Vertex Pharmaceuticals stock appears undervalued relative to the cash flows currently built into the model.

Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 12.5%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Does Vertex Pharmaceuticals Look Fairly Valued on Earnings?

The P/E ratio is a useful measure for Vertex Pharmaceuticals because earnings are a core focus for many investors in profitable biopharma companies. Vertex trades on a P/E of about 28.6x, which sits below the peer average near 37.4x and above the broader biotech industry average of about 17.3x. That places the stock between lower priced industry peers and higher priced direct comparables.

The fair P/E multiple for Vertex Pharmaceuticals, based on its profile, is estimated at about 27.7x, which is close to the current level. The gap between the actual P/E and this fair ratio is small. As a result, the market price appears broadly in line with what the model suggests given the company’s size, margins and risk profile, rather than clearly cheap or expensive on an earnings basis.

Overall, Vertex Pharmaceuticals appears roughly fairly valued on its current P/E multiple.

The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation work on Vertex Pharmaceuticals leaves off. They spell out what would need to happen to Vertex Pharmaceuticals' growth, margins and earnings for the stock to be worth meaningfully more or less than today’s price. Each Narrative sets out the assumptions behind its fair value so you can compare them with how the company actually performs over time. These Narratives sit on Simply Wall St's Community page.

Community views on Vertex Pharmaceuticals sit far apart, with one side leaning into the multi pillar growth story and the other focused on rising execution risk and cost pressure.

Bull case: 11% undervalued

"Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption…"

Bear case: 17% overvalued

"Regulatory scrutiny over drug pricing and increasing policy reforms in key markets such as the US and Europe are expected to intensify, which could directly limit Vertex's ability to maintain premium pricing for its specialty and orphan drugs, leading to pressured revenue growth and reduced net margins over the long term…"

Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For Vertex Pharmaceuticals, the Discounted Cash Flow (DCF) estimate points to some undervaluation, while the current P/E suggests the stock is priced about right compared with earnings. That split, together with the low broader value score, means the DCF signal should be treated as one input rather than a clear green light. What matters most from here is whether Vertex can convert its pipeline and recent moves into durable cash flows that justify both the intrinsic value estimate and the current multiple, without margin pressure or competition eroding that case.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.